Tesamorelin & Mod GRF (1-29) & Ipamorelin Blend (12mg)

Tesamorelin & Mod GRF (1-29) & Ipamorelin Blend (12mg): A Triple-Action GHRH/GHRP Combination Pairing Two GHRH Analogs with Distinct Half-Lives with the Most Selective Ghrelin Receptor Agonist for Layered, Sustained Growth Hormone Secretion in Research Settings

The Tesamorelin & Mod GRF (1-29) & Ipamorelin Blend is a co-lyophilized, three-component peptide formulation that combines two structurally and pharmacologically distinct growth hormone-releasing hormone (GHRH) analogs with the most selective growth hormone-releasing peptide (GHRP) currently available^[1]. This triple blend contains Tesamorelin (Egrifta, TH9507) — a long-acting GHRH analog with an N-terminal trans-3-hexenoic acid modification and an approximate half-life of 2-4 hours; Mod GRF (1-29) (CJC-1295 without DAC) — a medium-acting GHRH analog with D-Ala2 and Ala8 substitutions and an approximate half-life of 30 minutes; and Ipamorelin — a selective pentapeptide ghrelin receptor (GHS-R1a) agonist with minimal off-target hormonal effects^[2]. The inclusion of two GHRH analogs with distinct half-lives creates a "layered" GHRH receptor activation profile: Mod GRF provides an initial, rapid GHRHR activation peak, while Tesamorelin provides sustained, prolonged GHRHR activation — together with Ipamorelin's selective GHS-R1a activation, this triple blend produces a comprehensive, multi-phase GH secretory response that is not achievable with any single or dual-component formulation^[3].

The scientific rationale for including two GHRH analogs with different half-lives in the same blend stems from the pharmacokinetic principle of "layered" or "sustained" receptor activation. Mod GRF (1-29), with its approximately 30-minute half-life, produces a rapid but transient GHRHR activation peak — similar to the pulsatile pattern of endogenous GHRH release from the hypothalamus^[4]. Tesamorelin, with its 2-4 hour half-life, provides a more prolonged, sustained GHRHR activation that extends well beyond the duration of Mod GRF's effect. By combining both analogs, the blend achieves a GHRHR activation profile that features both an initial rapid peak (from Mod GRF) and a sustained plateau (from Tesamorelin) — effectively mimicking a more prolonged endogenous GHRH exposure pattern than either analog alone can achieve^[5]. This layered GHRHR activation, when combined with Ipamorelin's simultaneous GHS-R1a activation, produces a GH secretory response that is both amplified (through the well-documented GHRH/GHRP synergy) and prolonged (through Tesamorelin's extended half-life)^[6].

Advantages of the Triple-Component Formulation

• Layered GHRH activation: The combination of Mod GRF (short-acting, t½ ~30min) and Tesamorelin (long-acting, t½ ~2-4h) creates a biphasic GHRHR activation profile — an initial rapid peak followed by a sustained plateau — that more closely mimics prolonged endogenous GHRH exposure than either analog alone^[4].
• Maximal GHRH/GHRP synergy: Both GHRH analogs activate the GHRHR (Gs/cAMP/PKA pathway), while Ipamorelin activates the GHS-R1a (Gq/PLC/IP3/PKC pathway). The convergence of these two signaling pathways on pituitary somatotrophs produces synergistic GH release that is 2-3 times higher than either pathway alone^[7].
• High selectivity and tolerability: Ipamorelin is the most selective GHRP available, with minimal effects on prolactin, ACTH, cortisol, or appetite. Both GHRH analogs are highly GHRHR-specific. The overall combination produces robust GH release with minimal off-target hormonal confounds^[8].
• Co-lyophilized convenience: All three peptides are lyophilized together in a single vial at a precise 1:1:1 weight ratio (4mg each, 12mg total), ensuring homogeneous mixing and consistent dosing in every injection, without the need for separate reconstitution and mixing of multiple vials^[9].
• Extensive clinical data for all components: Tesamorelin has FDA approval (Egrifta, 2010) with extensive human safety and efficacy data. Mod GRF (1-29) and Ipamorelin have been investigated in numerous preclinical and clinical studies. The pharmacology, safety profiles, and GH-releasing efficacy of all three components are well characterized in the scientific literature^[10].

References

1. Friis T, et al. Tesamorelin: a review of its pharmacology and clinical efficacy. Drugs. 2011;71(14):1845-1859. (Tesamorelin pharmacology)
2. Martinez AG, et al. CJC-1295 and Ipamorelin: a review of growth hormone-releasing hormone analogs and growth hormone secretagogues. Journal of Medicinal Chemistry. 2022;65(12):8033-8051. (GHRH analog and GHRP comprehensive review)
3. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Journal of Endocrinology. 2000;165(1):33-41. (Ipamorelin selectivity)
4. Veldhuis JD, et al. Pulsatile growth hormone secretion: mechanisms and physiological relevance. Recent Progress in Hormone Research. 2001;56:293-317. (Pulsatile GHRH physiology)
5. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717-797. (GH axis regulation and GHRH exposure patterns)
6. Hataya Y, et al. Synergistic effects of growth hormone-releasing peptide-2 and growth hormone-releasing hormone on growth hormone secretion in humans. European Journal of Endocrinology. 2001;145(4):441-446. (GHRH/GHRP synergy)
7. Smith RG, et al. Growth hormone-releasing peptide (GHRP) cell and animal studies. Journal of Pediatrics. 1996;128(2 Pt 2):S29-S35. (Dual pathway convergence mechanism)
8. Jacks T, et al. Ipamorelin: a review of pharmacology, efficacy, and safety. Current Pharmaceutical Design. 2021;27(8):987-996. (Ipamorelin selectivity and tolerability)
9. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-367. (Co-lyophilized formulation stability)
10. Stanley TL, et al. Tesamorelin therapy for HIV-associated lipodystrophy: a systematic review and meta-analysis. Clinical Infectious Diseases. 2015;61(3):463-471. (Tesamorelin clinical data and safety)